Delivering monoclonal antibodies via inhalation: a systematic review of clinical trials in asthma and COPD

References

• GINA Main Repor. GINA main report - Global Initiative for Asthma - GINA; 2022. [cited 2023 Apr 30]. Available from: https://ginasthma.org/gina-reports/
   Google Scholar
• GOLD Report. Global initiative for chronic obstructive lung disease - GOLD; 2023. [cited 2023 May 4]. Available from: https://goldcopd.org/2023-gold-report-2/
   Google Scholar
• McGregor MC, Krings JG, Nair P, et al. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199:433–445. doi: 10.1164/RCCM.201810-1944CI
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386:157–171. doi: 10.1056/NEJMRA2032506
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Cavalli F, et al. An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. Biologics. 2021;15:363–374. doi: 10.2147/BTT.S295409
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40:724–741. doi: 10.1183/09031936.00213711
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: what does the future hold?. Semin Respir Crit Care Med. 2015;36:508–522. doi: 10.1055/S-0035-1555611
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Annibale R, et al. Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Rev Clin Pharmacol. 2021;14:1015–1027. doi: 10.1080/17512433.2021.1925537
   PubMed Web of Science ®Google Scholar
• Gea J. The future of biological therapies in COPD. Arch Bronconeumol. 2018;54:185–186. doi: 10.1016/J.ARBRES.2017.11.004
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84. doi: 10.1016/J.COPH.2020.11.003
   PubMed Web of Science ®Google Scholar
• Yousuf A, Ibrahim W, Greening NJ, et al. T2 biologics for chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract. 2019;7:1405–1416. doi: 10.1016/J.JAIP.2019.01.036
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Su X, Kwong B. Routes of delivery for biological drug products. Pharm Sci Encycl. 2013;1–48. doi: 10.1002/9780470571224.PSE521
   Google Scholar
• Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18:19–40. doi: 10.1038/NRD.2018.183
   PubMed Web of Science ®Google Scholar
• Johnson KA. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev. 1997;26:3–15. doi: 10.1016/S0169-409X(97)00506-1
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Panettieri RA, Taube C, et al. Development of an inhaled anti-TSLP therapy for asthma. Pulm Pharmacol Ther. 2023;78. doi: 10.1016/J.PUPT.2022.102184
   PubMed Web of Science ®Google Scholar
• Scheuch G, Kohlhaeufl MJ, Brand P, et al. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev. 2006;58:996–1008. doi: 10.1016/J.ADDR.2006.07.009
   PubMed Web of Science ®Google Scholar
• Liang Z, Ni R, Zhou J, et al. Recent advances in controlled pulmonary drug delivery. Drug Discovery Today. 2015;20(3):380–389. doi: 10.1016/J.DRUDIS.2014.09.020
   PubMed Web of Science ®Google Scholar
• Cazzola M, Cavalli F, Usmani OS, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Delivery. 2020;17(5):635–646. doi: 10.1080/17425247.2020.1739021
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Loukides S, Kostikas K. Revisiting IL-13 blockade: can we reach the wonderland the inhaled way? EBioMedicine. 2018;35:6–7. doi: 10.1016/J.EBIOM.2018.08.013
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. doi: 10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. doi: 10.1136/BMJ.N71
   Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inf Decis Mak. 2007 16;7. doi: 10.1186/1472-6947-7-16
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4
   PubMedGoogle Scholar
• Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999;160:1023–1027. doi: 10.1164/AJRCCM.160.3.9810012
   PubMed Web of Science ®Google Scholar
• Burgess G, Boyce M, Jones M, et al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018;35:67–75. doi: 10.1016/J.EBIOM.2018.07.035
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Hohlfeld JM, FitzGerald JM, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J. 2023;61:2201193. doi: 10.1183/13993003.01193-2022
   PubMed Web of Science ®Google Scholar
• Study of efficacy and safety of CSJ117 in patients with severe uncontrolled asthma - full text view - ClinicalTrials.Gov; n.d. [cited 2023 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT04410523
   Google Scholar
• Study of effect of CSJ117 on symptoms, pharmacodynamics and safety in patients with COPD - full text view - ClinicalTrials.Gov; n.d. [cited 2023 Apr 15]; Available from: https://clinicaltrials.gov/ct2/show/study/NCT04882124
   Google Scholar
• Knoch M, Wunderlich E, Geldner S. A nebulizer system for highly reproducible aerosol delivery. J Aerosol Med. 1994;7:229–237. doi: 10.1089/JAM.1994.7.229
   PubMedGoogle Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31. doi: 10.1016/J.ADDR.2014.04.004
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999–1022. doi: 10.1007/S11095-007-9475-1
   PubMed Web of Science ®Google Scholar
• Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18. doi: 10.1186/S12890-018-0662-0
   PubMed Web of Science ®Google Scholar
• Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353–363. doi: 10.2147/COPD.S18529
   PubMed Web of Science ®Google Scholar
• Respaud R, Vecellio L, Diot P, et al. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Delivery. 2015;12(6):1027–1039. doi: 10.1517/17425247.2015.999039
   PubMed Web of Science ®Google Scholar
• Hart TK, Sellers TS, Maleeff BE, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108:250–257. doi: 10.1067/MAI.2001.116576
   PubMed Web of Science ®Google Scholar
• Cruz-Teran C, Tiruthani K, McSweeney M, et al. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100–117. doi: 10.1016/J.ADDR.2020.12.004
   PubMed Web of Science ®Google Scholar
• Lightwood D, O’Dowd V, Carrington B, et al. The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol. 2013;425:577–593. doi: 10.1016/J.JMB.2012.11.036
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Rogliani P, et al. Therapeutic monoclonal antibodies for the treatment of chronic obstructive pulmonary disease. Drugs. 2016;76:1257–1270. doi: 10.1007/S40265-016-0625-9
   PubMed Web of Science ®Google Scholar
• Calzetta L, Aiello M, Frizzelli A, et al. The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: a systematic review. Biomedicines. 2021;9:1281. doi: 10.3390/BIOMEDICINES9091281
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Silkoff PE. Perspectives on exhaled nitric oxide. J Breath Res. 2017;11(4):047104. doi: 10.1088/1752-7163/AA7F0E
   PubMed Web of Science ®Google Scholar
• Al-Sajee D, Sehmi R, Hawke TJ, et al. Expression of IL-33 and TSLP and their receptors in asthmatic airways after inhaled allergen challenge. Am J Respir Crit Care Med. 2018;198:805–807. doi: 10.1164/RCCM.201712-2468LE
   PubMed Web of Science ®Google Scholar
• Wang W, Li Y, Lv Z, et al. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa. J Immunol. 2018;201:2221–2231. doi: 10.4049/JIMMUNOL.1800709
   PubMed Web of Science ®Google Scholar
• Huang C, Lowe AJ, Batt CA. Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market. Appl Microbiol Biotechnol. 2010;87:401–410. doi: 10.1007/S00253-010-2590-7
   PubMed Web of Science ®Google Scholar
• Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 2010;5:1663–1674. doi: 10.2217/FMB.10.125
   PubMed Web of Science ®Google Scholar
• Williams RO, Carvalho TC, Peters JI. Influence of particle size on regional lung deposition–what evidence is there? Int J Pharm. 2011;406:1–10. doi: 10.1016/J.IJPHARM.2010.12.040
   PubMedGoogle Scholar
• Liang W, Pan HW, Vllasaliu D, et al. Pulmonary delivery of biological drugs. Pharmaceutics. 2020;12:1–28. doi: 10.3390/PHARMACEUTICS12111025
   Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74. doi: 10.1038/NRD2153
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588–599. doi: 10.1046/J.1365-2125.2003.01892.X
   PubMed Web of Science ®Google Scholar
• Ecker DM, Dana Jones S, Levine HL. The therapeutic monoclonal antibody market the therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14. doi: 10.4161/19420862.2015.989042
   PubMed Web of Science ®Google Scholar
• Hussain A, Arnold JJ, Khan MA, et al. Absorption enhancers in pulmonary protein delivery. J Control Release. 2004;94:15–24. doi: 10.1016/j.jconrel.2003.10.001
   PubMed Web of Science ®Google Scholar
• Boegh M, Foged C, Müllertz A, et al. Mucosal drug delivery: barriers, in vitro models and formulation strategies. J Drug Deliv Sci Technol. 2013;23:383–391. doi: 10.1016/S1773-2247(13)50055-4
   Web of Science ®Google Scholar
• Miszczuk M, Dąbrowska M, Domagała I, et al. Differences in inhaler misuse between patients with asthma and COPD., Eur. Respir J. 2018;52:PA1010. doi: 10.1183/13993003.CONGRESS-2018.PA1010
   Web of Science ®Google Scholar
• Duarte-De-Araújo A, Teixeira P, Hespanhol V, et al. COPD: misuse of inhaler devices in clinical practice. Int J Chron Obstruct Pulmon Dis. 2019;14:1209–1217. doi: 10.2147/COPD.S178040
   PubMed Web of Science ®Google Scholar
• Mahon J, Fitzgerald A, Glanville J, et al. Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: a review and recommendations for the conduct of future research. Respir med. 2017;129:98–116. doi: 10.1016/j.rmed.2017.05.004
   PubMed Web of Science ®Google Scholar
• Çakmaklı S, Özdemir A, Fırat H, et al. An evaluation of the use of inhalers in asthma and chronic obstructive pulmonary disease. J Taibah Univ Med Sci. 2023;18:860–867. doi: 10.1016/J.JTUMED.2023.01.001
   PubMed Web of Science ®Google Scholar
• Volerman A, Carpenter D, Press V. What can be done to impact respiratory inhaler misuse: exploring the problem, reasons, and solutions. Expert Rev Respir Med. 2020;14:791–805. doi: 10.1080/17476348.2020.1754800
   PubMed Web of Science ®Google Scholar
• Settipane RA, Kreindler JL, Chung Y, et al. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. 2019;123:564–572.e3. doi: 10.1016/J.ANAI.2019.08.462
   PubMed Web of Science ®Google Scholar
• Menzella F. Baseline characteristics of patients enrolled in clinical trials of biologics for severe asthma as potential predictors of outcomes. J Clin Med. 2023;12:1546 doi: 10.3390/JCM12041546
   PubMed Web of Science ®Google Scholar
• Bodier-Montagutelli E, Mayor A, Vecellio L, et al. Designing inhaled protein therapeutics for topical lung delivery: what are the next steps? Expert Opin Drug Delivery. 2018;15(8):729–736. doi: 10.1080/17425247.2018.1503251
   PubMed Web of Science ®Google Scholar